Alumis Inc./$ALMS
1D1W1MYTD1Y5YMAX
Capital at risk
About Alumis Inc.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
- Ticker
- $ALMS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 238
- Headquarters
- South San Francisco, United States
- Website
- www.alumis.com
Alumis Inc. Metrics
BasicAdvanced
$1B
-
-$3.80
-0.67
-
Price and volume
Market cap
$1B
Beta
-0.67
52-week high
$31.35
52-week low
$3.76
Average daily volume
3.2M
Financial strength
Current ratio
6.744
Quick ratio
6.64
Long term debt to equity
0.07
Total debt to equity
0.081
Profitability
EBITDA (TTM)
-421.449
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-5,933.45%
Operating margin (TTM)
-5,744.48%
Effective tax rate (TTM)
0.40%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-45.34%
Return on equity (TTM)
-93.65%
Valuation
Price to revenue (TTM)
123.962
Price to book
2.26
Price to tangible book (TTM)
2.3
Price to free cash flow (TTM)
-2.607
Free cash flow yield (TTM)
-38.36%
Free cash flow per share (TTM)
-3.046
Growth
Revenue change (TTM)
-63.11%
Earnings per share change (TTM)
-0.13%
Upcoming events
No upcoming events
Alumis Inc. News
AllArticlesVideos
Funds containing Alumis Inc.
AllUSDEURGBP
Fund name | Fund size | $ALMS weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.08% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.08% |
iShares Healthcare Innovation£DRDR | £1B | 0.08% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.